The locus coeruleus-noradrenergic system exerts an activating influence on forebrain neuronal and behavioral activity states, in part through the actions of noradrenergic ␤-receptors in the medial septal (MS) and medial preoptic (MPOA) areas. MPOA ␣1-receptors exert similar wake-promoting actions. The current study examines the influence of ␣1-receptors located within MS on sleep-wake state. In addition, the extent to which ␣1-and ␤-receptors located within MS and MPOA interact in the modulation of behavioral state was investigated by examining the effects of individual or combined infusion of ␣1-and ␤-agonists into these regions. Results show that ␣1-receptors located within MS exert wake-promoting actions. Within both MS and MPOA, additive wake-promoting actions were observed with ␣1-and ␤-receptor stimulation, the sum of which contributes to the overall arousal state of the animal.
The locus coeruleus-noradrenergic system exerts an activating influence on forebrain neuronal and behavioral activity states, in part through the actions of noradrenergic ␤-receptors in the medial septal (MS) and medial preoptic (MPOA) areas. MPOA ␣1-receptors exert similar wake-promoting actions. The current study examines the influence of ␣1-receptors located within MS on sleep-wake state. In addition, the extent to which ␣1-and ␤-receptors located within MS and MPOA interact in the modulation of behavioral state was investigated by examining the effects of individual or combined infusion of ␣1-and ␤-agonists into these regions. Results show that ␣1-receptors located within MS exert wake-promoting actions. Within both MS and MPOA, additive wake-promoting actions were observed with ␣1-and ␤-receptor stimulation, the sum of which contributes to the overall arousal state of the animal.
Cortical and thalamic neurons display distinct activity patterns across sleep-wake states that are associated with differential information-processing properties (Livingstone & Hubel, 1981; McCormick & Bal, 1997; Steriade & Buzsaki, 1990; Steriade, McCormick, & Sejnowski, 1993) . Within the waking state, forebrain neuronal activity state, as illustrated by electroencephalographic (EEG) measures, is closely correlated with higher cognitive processes such as vigilance (Makeig & Inlow, 1993) . Substantial evidence indicates that the locus coeruleus (LC) noradrenergic system modulates behavioral and forebrain neuronal activity states (Berridge & Foote, 1991; Berridge, Page, Valentino, & Foote, 1993) . For example, alterations in LC neuronal discharge rates precede changes in behavioral and EEG indices of behavioral state (Aston-Jones & Bloom, 1981a; Foote, Aston-Jones, & Bloom, 1980; Hobson, McCarley, & Wyzinski, 1975) . Moreover, unilateral activation of LC neurons elicits a robust, bilateral activation of forebrain EEG in the halothane-anesthetized rat (Berridge & Foote, 1991) , whereas bilateral suppression of LC discharge activity increases EEG and behavioral measures of sedation (Berridge et al., 1993; Correa-Sales, Rabin, & Maze, 1992; De Sarro, Ascioti, Froio, Libri, & Nistico, 1987; De Sarro, Bagetta, Ascioti, Libri, & Nistico, 1988; Waterman, Livingston, & Bouchenafa, 1988) .
Noradrenergic efferents influence behavioral and EEG activity states within an extended region of the medial basal forebrain encompassing the medial septal area (MS) and the medial preoptic area (MPOA) through actions at ␤-and/or ␣1-noradrenergic receptors. For example, in the unanesthetized animal, direct infusion of norepinephrine (NE) or the indirect acting noradrenergic agonist, amphetamine, into either MS or MPOA elicits sustained increases in waking (Berridge & O'Neill, 2001; Berridge, O'Neil, & Wifler, 1999; Kumar, Datta, Chhina, & Singh, 1986; Mohan, Datta, Chhina, Gandhi, & Singh, 1984) . Infusions placed immediately adjacent to these regions, including within the substantia innominata, do not have a similar influence on behavioral state. Similar wake-promoting actions are observed following infusion of a direct acting ␤-agonist into either of these regions (Berridge & O'Neill, 2001; Mallick & Alam, 1992) . Although wake-promoting actions are observed with ␣1-agonist infusion into MPOA, it is not known whether ␣1-receptors located within MS modulate forebrain EEG and/or behavioral activity state.
The above-described observations indicate a prominent role of medial basal forebrain ␤-(MS and MPOA) and ␣1-receptors (at least within MPOA) in the modulation of forebrain neuronal activity patterns associated with alert waking. To date, the extent to which combined stimulation of these two receptor subpopulations exert redundant, additive, or supra-additive wake-promoting actions is unknown. The goals of the current study were two-fold. First, the extent to which MS ␣1-receptors modulate behavioral state was examined. The results demonstrated dose-dependent and sustained increases in waking following ␣1-agonist infusion into, but not outside, MS. These effects are similar to those observed previously with ␤-agonist infusion into this region. Second, the extent to which MS and MPOA ␣1-and ␤-receptors interact to modulate behavioral state was examined by investigating the wake-promoting effects of ␣1-and ␤-agonists infusions into MS and MPOA, either individually or in combination. Results indicate that within both MS and MPOA, ␣1-and ␤-receptors exert unique (nonredundant, additive) wake-promoting actions that contribute to the overall arousal state of the animal. These actions likely play a prominent role in the maintenance of forebrain activity states and the performance of state-dependent cognitive and affective processes associated with alert waking.
Method

Subjects and Surgery
Male Sprague-Dawley rats (300 -400 g; Charles River, Wilmington, MA) were housed in pairs for approximately 7 days prior to surgery, with ad-lib access to food and water, on an 11:13-hr light-dark cycle (lights on 0700). Rats were anesthetized with halothane and then placed in a stereotaxic instrument with the incisor bar set at Ϫ11.5 mm below ear bar zero. Twenty-six gauge guide cannulas (Plastics One, Roanoke, VA) were implanted bilaterally aimed at either MS (A Ϫ0.9, L 1.6, V Ϫ2.8) or MPOA (A Ϫ1.9, L 1.8, V Ϫ3.4) at an angle of 8°from vertical. A bipolar EEG electrode was implanted into the frontal cortex (A 3.0, L Ϯ1.5, V 1.5), and a bipolar electromyographic (EMG) electrode was implanted into the dorsal neck muscle (see below). All coordinates are relative to bregma unless otherwise noted. The cannulas and electrodes were cemented into position with acrylic cement (Plastics One). A stainless steel wire stylet was inserted and attached to each cannula with a threaded plastic connector. The rats were allowed to recover for 7-10 days before testing. All efforts were made to minimize animal suffering and to minimize the number of subjects used, and all experiments were conducted in accordance with the National Institutes of Health principles of laboratory animal care (Publication No. 80 -23, revised 1996) .
Infusions and Experimental Procedures
On the day prior to testing, rats were transferred to testing chambers where they were housed individually. The Plexiglas testing chamber (32 cm long ϫ 32 cm wide ϫ 40 cm high) was housed in a wooden, sound-attenuating outer chamber containing a 15-W light bulb, a speaker through which white noise (80 dB) was played, and a 12-V fan running at reduced speed. A 10-cm hole in the top panel of the outer chamber permitted entry of infusion lines and EEG cables. The stylet was removed, and a stainless steel coil spring was threaded onto the cannula by means of plastic threaded sleeves (Plastics One). The other end of the spring was attached to a liquid swivel (Instech Laboratories, Plymouth Meeting, PA) held in a counterbalance outside the outer chamber. EEG/EMG electrodes were connected to a field effect transistor headstage, the cables of which were connected to a counterbalance located outside the outer chamber. The rats had free access to food and water.
On the day of testing, between the hours of 0800 and 1000, the stainless steel coil spring, connected the previous day, was disconnected. A 33-gauge needle (Plastics One) was connected to a length of PE-20 tubing filled with water and housed within a stainless steel coil spring. The distal end of the PE-20 tubing was attached to the outlet of the liquid swivel. The inlet of the liquid swivel was connected to a 10-l syringe by a length of PE-20 tubing filled with water. An air bubble was placed in the tubing above the liquid swivel to permit visualization of fluid displacement during advancement of the syringe plunger. The infusion needle and PE-20 tubing were loaded with vehicle or drug dissolved in vehicle (0.01 nmol/250 nl; 0.07 nmol/250 nl). Artificial extracellular fluid (AECF, 147 mM NaCl, 1.3 mM CaCl 2 , 0.9 mM MgCl 2 , 2.5 mM KCl, 5.0 mM NaH 2 PO 4 ; pH 7.4) served as vehicle. An approximately 50-nl air bubble was used to separate the vehicle or drug from water contained within the PE-20 tubing. The plunger of the syringe was advanced by a microprocessor-controlled infusion pump (Harvard Apparatus, South Natick, MA). The needle was inserted and secured to the cannula by plastic threaded sleeves. Needle insertion was typically performed without the rat being handled.
After rats went to sleep (typically 30 -90 min after handling) cortical EEG/EMG recording was initiated. Following 60 min of baseline recording, during which rats spent the majority of the time asleep, a 250-nl infusion (over 100 s) was made. Recording continued for an additional 90 min. However, the first 15 min of postinfusion data were excluded from analysis. This was based on pilot studies that indicated a delay of approximately 10 min for onset of drug effects. Each rat was tested twice, once for each cannula.
Drugs
Isoproterenol (Iso) and phenylephrine (Phen; both from Sigma, St. Louis, MO) were dissolved in AECF. Solution concentrations were 4 g/l for Iso and 8 g/l for Phen. The Phen/Iso treatment groups received Iso and Phen dissolved at concentrations of 4 g/l and 8 g/l, respectively. Doses were chosen on the basis of previous studies Berridge & O'Neill, 2001 ) and a limited number of pilot studies that determined doses that produced moderate, not maximal, increases in waking.
EEG and EMG Recording and Analyses
A bipolar surface-to-depth electrode was used to record cortical EEG (A ϩ3.0, L Ϯ1.5). EMG was recorded with two 4-cm lengths of flexible, insulated wire (Cooner Wire, Chatsworth, CA) threaded into neck muscle and positioned such that an approximately 3-mm portion of exposed wire was in direct contact with tissue. A screw electrode was placed over the cerebellum and served as ground. The ends of the EEG, EMG, and screw electrodes were then inserted into a five-pin plastic connector. EEG and EMG signals were amplified and filtered (0.3-100.0 Hz, EEG; 1.0 -30.0 Hz, EMG) and recorded on a polygraph and VCR recording tape.
EEG and EMG were scored for the following behavioral state categories: slow-wave sleep (high-voltage EEG, low-voltage EMG), REM sleep (low-voltage EEG combined with EMG activity approximately 50% lower amplitude than that observed in slow-wave sleep, with occasional shortduration, large-amplitude deflections caused by muscle twitches), quiet waking (low-voltage EEG with EMG activity of an average amplitude twice that observed in slow-wave sleep), and active waking (low-voltage EEG, sustained high-voltage EMG of approximately twice that observed in quiet waking, with frequent movement deflections). To be scored as a distinct epoch, the appropriate EEG and EMG activity patterns needed to persist for a minimum of 15 s. Time spent in each state was scored and totaled for the five or four 30-min epochs of the observation period, depending on the study. These included the two segments immediately prior to infusions (Pre 1 ϭ 0 -30 min; Pre 2 ϭ 30 -60 min) and either three segments beginning immediately after infusions (Post 1 ϭ 60 -90 min; Post 2 ϭ 90 -120 min; Post 3 ϭ 120 -150 min) or two segments beginning 15 min after infusions (Post 1 ϭ 75-105 min; Post 2 ϭ 105-135 min). All scoring of EEG and EMG was conducted by observers who were unaware of the experimental conditions.
Statistical Analyses
For infusions into MS and MPOA, EEG/EMG effects were analyzed statistically with a two-way mixed-design analysis of variance with drug treatment as the between-subjects variable and time as the within-subjects variable. Post hoc analyses were conducted with Tukey's honestly significant difference test.
Histology and Data Selection
Rats were deeply anesthetized and perfused transcardially with at least 60 ml of 4% formaldehyde. The brain was removed and placed in fixative for at least 24 hr. The brain was then frozen, and 40-m sections through MS and MPOA were cut and collected. The presence and extent of the spread of Pontamine Sky Blue dye (Sigma, St. Louis, MO) in freshly sectioned tissue was noted to determine whether fluid had exited the needle and the location of the center of the infusion site. The latter is important in cases in which the infusate diffused dorsally along the length of the needle rather than radially, from the tip of the needle into tissue. The sections were stained with Neutral-Red dye for subsequent examination of the infusion sites. Data were included only for those cases in which the EEG/EMG recordings were electrically adequate; histological analyses verified both accurate placement of infusion needles and that infusate entered tissue and was centered around the tip of the infusion needle.
Results
Effects of ␣1-Receptor Stimulation Within MS on Sleep and Waking
Previous studies demonstrated robust wake-promoting actions of ␤-receptors located within, but not anterior, lateral, or dorsal to MS (Berridge, Bolen, Manley, & Foote, 1996; . To assess the wake-promoting actions of MS ␣1-receptor stimulation, 250-nl infusions of either vehicle or 10 nmol or 50 nmol Phen were made into MS in sleeping rats ( Figure 1A ). As reported previously Berridge & O'Neill, 2001) , the rats slept for the majority of time prior to infusions. No significant differences in total time spent awake or asleep were observed before or after vehicle infusions into MS or MPOA (see below). Thus, data from these vehicle-treated groups were combined for statistical analyses. In contrast, as shown in Figures 2-4 , Phen infusion elicited a dose-dependent increase in total time spent awake: treatment, F(2, 19) ϭ 31.1, p Ͻ .001; time, F(4, 76) ϭ 24.5, p Ͻ .001; Treatment ϫ Time, F(8, 76) ϭ 7.1, p Ͻ .001. Similar to that observed previously with ␤-receptor agonist infusion, Phen infusions outside MS, either laterally (n ϭ 6) or anteriorally (n ϭ 5), had no consistent wake-promoting actions ( Figure 3 ). As shown in Figure 4 , total time spent awake was significantly increased during the Post 1 epoch in both the 10 nmol and 50 nmol Phen groups and during the Post 2 and Post 3 epochs for the 50 nmol group. Latency to waking was 1209 Ϯ 340 s (range ϭ 0 -2,587 s) for the 10-nmol dose and 159 Ϯ 73 s (range ϭ 0 -411 s) for the 50-nmol dose, measured from the end of the 100-s infusion.
The Phen-induced increase in total time spent awake resulted from significant increases in both quiet waking: treatment, F(2, 19) ϭ 9.4, p ϭ .001 (see Figure 4) ; time, F(4, 76) ϭ 10.9, p Ͻ .001; Treatment ϫ Time, F(8, 76) ϭ 3.3, p ϭ .003, and active waking: treatment, F(2, 19) ϭ 17.8, p Ͻ .001 (see Figure 4) ; time, F(4, 76) ϭ 11.7, p Ͻ .001; Treatment ϫ Time, F(8, 76) ϭ 5.6, p Ͻ .001. Phen-induced waking was associated with decreases in slowwave sleep: treatment, F(2, 19) ϭ 20.8, p Ͻ .001; time, F(4, 76) ϭ 23.1, p Ͻ .001; Treatment ϫ Time, F(8, 76) ϭ 7.5, p Ͻ .001, and REM sleep: treatment, F(2, 19) ϭ 9.7, p ϭ .001; time, F(4, 76) ϭ 2.8, p ϭ .03; Treatment ϫ Time, F(8, 76) ϭ 0.5, p ϭ .23. These effects of ␣1-agonist infusion on sleep and waking are similar to those observed previously with ␤-receptor stimulation within MS .
Behavioral observations indicated that Phen-induced waking was accompanied by minimal levels of locomotor activity as Before the infusion, the rat spent the majority of time in slow-wave sleep (resting with large-amplitude, slowwave ECoG activity and low-amplitude EMG activity). After the infusion, the rat was awake, as reflected by the decrease in large-amplitude, slowwave ECoG activity and the increase in EMG amplitude. measured by quadrant entries and rears or other behaviors typically not associated with spontaneous daytime waking (data not shown).
Effects of Combined ␣1-and ␤-Receptors Within MPOA and MS on Sleep and Waking
EEG/EMG effects of combined ␣1-and ␤-agonist infusion into MS. The above-described experiments and previous studies (e.g., demonstrate independent wakepromoting actions of ␣1-and ␤-receptor stimulation within MS.
To determine the effects of combined ␣1-and ␤-receptor stimulation within MS on sleep and waking, in this experiment we examined the sleep-wake effects of small infusions of ␣1-and ␤-agonists individually and in combination ( Figure 5) . Previous studies have amply demonstrated that infusion of direct-acting ␤-agonists or indirect-acting noradrenergic agonists (amphetamine) does not elicit alterations in behavioral state when placed immediately outside the general region of MS (anteriorally, dorsally, or laterally; Berridge et al., , 1999 . These studies delineate unambiguously the borders of a circumscribed region encompassing the medial septum and diagonal band of Broca within which noradrenergic ␣1-and ␤-receptors act to modulate behavioral state. Thus, in the current experiments, we examined the effects of combined stimulation of ␣1-and ␤-receptor stimulation within, but not outside, this region.
Doses of the ␤-agonist Iso (4 nmol) and the ␣1-agonist Phen (10 nmol) were chosen that individually produced modest increases in waking when infused into this region, as determined from a limited number of pilot studies. At these doses, latency to waking can exceed 10 -15 min. Thus, to better quantify the magnitude of the wake-promoting effects of individual and combined receptor stimulation, postinfusion analyses were not begun until 15 min after infusion.
Rats received infusions of vehicle (n ϭ 8), either drug alone (Iso, n ϭ 8; Phen, n ϭ 8), or both drugs in combination (Phen/Iso, n ϭ 8). There were significant effects of treatment, F(3, 28) ϭ 11.8, p Ͻ .001; time, F(3, 84) ϭ 23.9, p Ͻ .001; and a Treatment ϫ Time interaction, F(9, 84) ϭ 3.3, p ϭ .002, on total time spent awake. There were also significant effects of treatment, F(3, 28) ϭ 10.9, p Ͻ .001; time, F(3, 84) ϭ 17.9, p Ͻ .001; and Treatment ϫ Time, F(9, 84) ϭ 2.4, p ϭ .018, on slow-wave sleep. For REM sleep, although there was not a significant effect of treatment, F(3, 28) ϭ 1.9, p ϭ .151, there were significant effects of time, F(3, 84) ϭ 6.1, p Ͻ .001, and Treatment ϫ Time, F(9, 84) ϭ 1.2, p ϭ .284. Within waking, there were significant effects of treatment, F(3, 28) ϭ 9.0, p Ͻ .001, time, F(3, 84) ϭ 15.2, p Ͻ .001, and a Treatment ϫ Time interaction, F(9, 84) ϭ 2.13, p ϭ .036, on quiet waking. Active waking appeared to be affected to a lesser extent by these variables: treatment, F(3, 28) ϭ 1.03 p ϭ .395; time, F(3, 84) ϭ 7.9, p Ͻ .001; Treatment ϫ Time, F(9, 84) ϭ 1.4, p ϭ .219.
At the doses used, infusion of either the ␣1-or ␤-agonist individually into MS elicited relatively weak effects on measures of sleep and waking ( Figure 5 ). For example, out of a possible 1,800 s per 30-min testing epoch, Iso elicited approximately 735 s of total waking in the first postinfusion epoch and Phen elicited approximately 890 s of total waking. Post hoc analyses indicated that across Post 1 and Post 2 epochs, a significant increase in total waking and a significant decrease in slow-wave sleep was observed only in Phen-treated rats during the Post 1 epoch. Further, neither Phen nor Iso infused individually elicited significant alterations in quiet waking, active waking, or REM sleep.
In contrast, when infused in combination, Phen/Iso elicited greater and more sustained increases in waking and decreases in sleep than that observed in either the Phen or Iso treatment groups ( Figure 5 ). For example, Phen/Iso-treated rats displayed significantly increased levels of total time spent awake during both Post 1 and Post 2 epochs. During the Post 1 epoch, total time spent awake Figure 3 . Schematic depiction of the location of each 50-nmol phenylephrine (Phen) infusion and time spent awake following infusion. Symbols indicate site of the infusion needle tip. Numerals specify the appropriate time range (1 ϭ 0 -1,000 s, 2 ϭ 1,000 -2,000 s, 3 ϭ 2,000 -2,500 s, 4 ϭ 2,500 -3,000 s, 5 ϭ Ͼ 3,000 s) for total time spent awake during the 60-min postinfusion interval for each rat. Vehicle-treated rats displayed a mean total time awake in this period of 685 Ϯ 87 s (range ϭ 410 -1,012 s). These infusions identify a region within which Phen infusions increase waking, which encompasses the medial septum (MS), the vertical limb of the diagonal band of Broca, the islands of Calleja, and posterior portions of the shell region of the nucleus accumbens (NA). This region, identified by the dotted line border, is identical to the region previously identified as being involved in ␤-receptor-mediated waking and is collectively referred to as the medial septal area. Infusions outside this region were substantially less effective at increasing waking beyond that observed in preinfusion epochs or in vehicle-treated rats. CC ϭ corpus callosum; CP ϭ caudateputamen; LV ϭ lateral ventricle; LS ϭ lateral septum; AC ϭ anterior commissure. Numbers below panel refer to coronal level relative to bregma (modified from Swanson, 1992) .
was significantly higher for Phen/Iso-treated rats than for Isotreated rats. A similar pattern of effects was observed with Phen/ Iso-induced suppression of slow-wave sleep. In contrast to that observed with either drug treatment alone, Phen/Iso-treated rats displayed significantly greater levels of quiet waking during both Post 1 and Post 2 epochs.
EEG/EMG effects of combined ␣1-and ␤-agonist infusion into MPOA. Similar studies were conducted to determine the sleepwake effects of combined ␣1-and ␤-receptor stimulation within MPOA ( Figure 1B, Figure 6 ). Similar to the effects described for MS, previous pharmacological mapping studies demonstrate that infusions of NE, amphetamine, or direct acting noradrenergic receptor agonists do not act immediately outside MPOA to modulate behavioral state (including dorsal to MPOA; Berridge et al., 1999; Berridge & O'Neill, 2001) . In the present study, rats received infusions of vehicle, either drug alone, or both drugs in combination. Infusions into MPOA elicited a pattern of sleep-wake effects that was qualitatively similar to that observed with infusions into MS. There were significant effects on total time spent awake: treatment, F(3, 28) Similar to that observed with infusions into MS, ␣1-or ␤-receptor stimulation alone elicited significant, though modest, increases in total time spent awake (Figure 6 ). Post hoc analyses indicated that Iso-and Phen-induced increases in total waking were only statistically significant during the first postinfusion epoch (Post 1). This increase in total waking resulted from modest increases in both quiet and active waking. In general, the effects of both Phen and Iso on quiet and active waking across the two postinfusion epochs were not statistically significant. The only exception to this was a significant increase in quiet waking observed in the first postinfusion epoch in Phen-treated rats. Similarly, infusion of either receptor agonist alone elicited relatively small decreases in slow-wave sleep, which were statistically significant only for the Phen-treated group during the Post 1 epoch. Phen, but not Iso, significantly decreased REM sleep during Post 1, but not during Post 2.
Simultaneous infusion of Phen and Iso elicited substantially greater increases in total time spent awake and decreases in slowwave sleep than those observed with treatment with either drug individually (Figure 6 ). In the combined treatment group, the Figure 5 . Effects of individual and combined ␣1-and ␤-receptor stimulation within the medial septal area (MS) on distinct sleep-wake states. Shown are the effects of vehicle, 4 nmol isoproterenol (Iso), 10 nmol phenylephrine (Phen), or 4 nmol Iso ϩ 10 nmol Phen (Combined) infused into MS on total time spent awake (total waking) and in slow-wave sleep, quiet waking, active waking, and REM sleep. Symbols represent mean (ϮSEM) time spent in a given behavioral state per 30-min epoch. PRE1 and PRE2 represent preinfusion epochs. POST1-POST3 represent postinfusion epochs, beginning immediately following infusion. Combined stimulation of ␣1-and ␤-receptors elicited substantially larger increases in measures of waking and decreases in measures of both slow-wave and REM sleep than stimulation of either receptor subtype individually. During POST2, the only significant alteration in sleep-wake state was observed in the combined-treated rats. The lack of visible error bars indicates that the magnitude of the SEM fell within the range corresponding to the dimensions of the symbol. * p Ͻ .05, ** p Ͻ .01 compared with vehicle-treated controls. ϩp Ͻ .05 compared with combined-treated rats. increase in total waking and the decrease in slow-wave sleep were statistically significant during both the Post 1 and Post 2 epochs. During Post 1, the Phen/Iso-induced increase in total waking and decrease in slow-wave sleep were significantly greater than those observed with either ␤-or ␣1-receptor stimulation alone. The increase in total time spent awake resulted from significant increases in both quiet and active waking during the Post 1 epoch and significant increases in quiet waking during the Post 2 epoch. A similar pattern of effects was observed for slow-wave sleep, with significant decreases observed in the Phen/Iso-treated rats during both the Post 1 and Post 2 testing epoch.
Discussion
MS ␣1-Receptors Exert Wake-Promoting Actions
Noradrenergic systems modulate forebrain neuronal and behavioral activity states (Aston-Jones & Bloom, 1981b; Berridge & España, 2000; Berridge & Foote, 1991 Berridge & O'Neill, 2001; Foote et al., 1980; Hobson et al., 1975) . At least some of these modulatory actions derive from actions of NE within a circumscribed region of the medial basal forebrain that extends, rostrocaudally, from the anterior aspect of MS to the posterior aspect of MPOA Figure 6 . Effects of individual and combined ␣1-and ␤-receptor stimulation within the medial preoptic area (MPOA) on distinct sleep-wake states. Shown are the effects of vehicle, 4 nmol isoproterenol (Iso), 10 nmol phenylephrine (Phen), or 4 nmol Iso ϩ 10 nmol Phen (Combined) infused into MPOA on total time spent awake (total waking) and in slow-wave sleep, quiet waking, active waking, and REM sleep. Symbols represent mean (ϮSEM) time spent in a given behavioral state per 30-min epoch. PRE1 and PRE2 represent preinfusion epochs. POST1-POST3 represent postinfusion epochs, beginning immediately following infusion. Combined stimulation of ␣1-and ␤-receptors elicited substantially larger increases in measures of waking and decreases in measures of both slow-wave and REM sleep than stimulation of either receptor subtype individually. During POST2, the only significant alteration in sleep-wake state was observed in the combined-treated rats. The lack of visible error bars indicates that the magnitude of the SEM fell within the range corresponding to the dimensions of the symbol. * p Ͻ .05, ** p Ͻ .01 compared with vehicle-treated controls. ϩp Ͻ .05 compared with combined-treated rats. Berridge & O'Neill, 2001; Kumar et al., 1986; Mallick & Alam, 1992; Mohan et al., 1984) . Previous work has demonstrated that within MPOA, stimulation of both ␤-and ␣1-receptors elicits sustained epochs of alert waking (Berridge & O'Neill, 2001; Mallick & Alam, 1992) . Although similar wake-promoting actions of MS ␤-receptors have also been observed , the extent to which ␣1-receptors exert similar behavioral state-modulatory actions had not been examined previously. The current study demonstrates that ␣1-receptors located within MS exert robust wake-promoting actions. The anatomical boundaries within which MS ␣1-agonist infusion elicits waking appear identical to those observed with ␤-agonist infusions . Further, similar to that observed with infusions of a ␤-receptor agonist and amphetamine (Berridge et al., 1999) , waking elicited by ␣1-receptor agonist infusion into MS resembled spontaneous daytime waking. Thus, following these infusions, behaviors typically associated with spontaneous waking were observed (grooming, drinking, eating) in the absence of excessive locomotor activity or otherwise atypical behavior. This is the first demonstration of behavioral state-altering actions of MS ␣1-receptors. In combination with previous studies, these observations demonstrate that noradrenergic efferents exert wake-promoting actions through activation of both ␣1-and ␤-noradrenergic receptors located within an extended region of the medial basal forebrain encompassing both MS and MPOA.
␣1-and ␤-Receptors Located Within MS and MPOA Exert Additive Wake-Promoting Actions
The current and previous studies demonstrate robust wakepromoting actions of MS and MPOA ␣1-and ␤-receptors. Under normal physiological conditions, NE, released from noradrenergic efferents, acts simultaneously at both ␣1-and ␤-receptors. Prior to the current study, the consequence of combined actions of these receptor subpopulations on sleep-wake state had yet to be determined. To better elucidate the net action of these receptors in the regulation of behavioral state, the current study examined the sleep-wake effects of microinfusion of ␣1-and ␤-agonists, either individually or in combination, into MS and MPOA. The results suggest that ␣1-and ␤-receptors located within both MS and MPOA exert nonredundant and largely additive wake-promoting actions. During quiet waking, LC neurons display relatively low discharge rates that are well below rates observed under higharousal conditions, particularly during self-directed behaviors such as grooming and eating (Aston-Jones & Bloom, 1981a; Foote et al., 1980) . These observations are consistent with previous observations in halothane-anesthetized rats, in which bilateral suppression of LC discharge rates resulted in synchronous EEG activity only when LC discharge was suppressed greater than approximately 85% (Berridge et al., 1993) . The current observations suggest that combined actions of ␣1-and ␤-receptors within MS and MPOA may be sufficient to maintain an activated forebrain, even under relatively low rates of NE release associated with relatively low levels of LC discharge activity.
Depending on testing epoch and behavioral state variables, there were instances in which only combined ␤-and ␣1-receptor stimulation elicited statistically significant alterations in behavioral state. Thus, from a perspective of statistical significance, it could be argued that simultaneous stimulation of ␣1-and ␤-receptors exerts synergistic arousal-enhancing effects. Nonetheless, qualitatively, the pattern of behavioral state effects observed in the current study suggests that the nature of the interaction between ␣1-and ␤-receptor stimulation in the regulation of behavioral state is more additive than synergistic.
Previous studies demonstrated that combined actions of ␣1-and ␤-receptors are necessary for the maintenance of normal EEG and behavioral indices of arousal, at least under certain environmental conditions (Berridge & España, 2000) . For example, peripheral administration of an ␣1-antagonist combined with central administration of a ␤-antagonist elicits a profound increase in slow-wave activity under high-arousal conditions. This effect is not observed with blockade of either noradrenergic receptor subtype individually (Berridge & España, 2000; Stone & Quartermain, 1999) . The current observations suggest that MS and MPOA ␣1-and ␤-receptors likely contribute to the synergistic sedative effects of ␣1-and ␤-receptor blockade.
Circuitry Underlying Arousal-Enhancing Actions of MS and MPOA Noradrenergic Receptors
The region of the basal forebrain within which NE acts to induce the alert waking state encompasses anatomically distinct subregions (MS vs. MPOA) that have traditionally been associated with dissimilar behavioral functions. Whether the wake-promoting actions of NE within MS and MPOA reflect direct or indirect actions on arousal-related circuits remains unclear. For example, each region may contain circuitry that evolved for the purpose of behavioral state regulation. Alternatively, these regions may have evolved to support distinct, and possibly highly divergent, behavioral processes, each of which requires the alert waking state. In this case, rather than containing circuitry that supports alert waking, each region may send efferents to similar arousal-controlling circuits that ensure coordination of the appropriate behavioral state with the state-dependent behavioral functions subserved by each region.
Currently, little is known regarding the localization of either ␣1-or ␤-receptors across different neuronal populations located within either MS or MPOA. Within MS, the combined action of cholinergic and GABAergic neurons has been demonstrated to influence hippocampal neuronal activity state (Colom, Nassif-Caudarella, Dickson, Smythe, & Bland, 1991) . Noradrenergic efferents may modulate one or both of these ascending modulatory pathways to influence activity state of the forebrain. Alternatively, noradrenergic modulation of behavioral state within MS may involve alterations in efferent pathways to other regions involved in the regulation of behavioral state, such as hypothalamus, thalamus, or midbrain. Such efferents could be direct projections to these regions (Cunningham, Nissen, & Renaud, 1993; Meibach & Siegel, 1977; Swanson & Cowan, 1979) or indirect projections via hippocampal efferents (Ino et al., 1988; Swanson & Cowan, 1977; Walaas & Fonnum, 1980) . The degree to which ␤-and ␣1-receptors are differentially localized within neurochemically and/or anatomically defined ascending or descending neuronal populations remains to be determined. If MS and/or MPOA ␣1-and ␤-receptors are located on the same cell, these receptors could interact to influence the activity state of that neuron by at least two mechanisms. First, through parallel actions on second messenger systems (e.g. phosphoinostol/diacylglycerol vs. cAMP), these receptors could exert independent and additive effects on membrane potential. In addition, evidence indicates that ␣1-receptors can potentiate ␤-receptor-mediated cAMP production (Stone, McEwen, Herrera, & Carr, 1987) . A similar mechanism might contribute to the additive wake-promoting effects of medial basal forebrain ␣1-and ␤-receptor stimulation.
Summary
The first experiment demonstrated that within MS, ␣1-receptors exert wake-promoting actions similar to those described previously for MS ␤-receptors. Combined with results from previous studies, these observations demonstrate that noradrenergic ␣1-and ␤-receptors located within the region of the medial basal forebrain encompassing both MS and MPOA exert behavioral statemodulatory actions. Additional experiments demonstrated that within this region, these two receptor subpopulations exert additive (nonredundant) wake-promoting actions, the sum of which contributes to the overall arousal state of the animal. These results further indicate a prominent role of central noradrenergic systems in the regulation of behavioral state and state-dependent cognitive and affective processes.
